Skip to main content

Advertisement

Table 4 Clinical studies investigating toxicity and outcome of SBRT with FFF beams

From: Safety of high-dose-rate stereotactic body radiotherapy

  Current study Wang 2014 [ 31 ] Prendergast 2013 [ 29 ] Alongi 2013 [ 26 ] Navarria 2013 [ 28 ] Alongi 2012 [ 27 ] Scorsetti 2011 [ 30 ]
Patients (Lesions) 84 (100) 20 (22) 64 40 46 25 (28) 67 (70)
Tumor Various (mostly lung) HCC Lung Prostate NSCLC Stage I Abdominal/pelvic LN Various (mostly lung)
RT schedule 21 – 66 Gy (3–15 fx) 40 - 75 Gy (3–10 fx) 30 – 60 Gy (3–5 fx) 35 Gy (5 fx) 48 Gy (4 fx) 45 Gy (6 fx) 32 – 75 Gy (3–6 fx)
Median follow-up (range) 11 months (3–46) 7 months (3–13) 12 months (3–25) 11 months (5–16) 16 months (2–24) 6 months (2–19) NA7
Acute toxicity 1≥ G3 0% 5%3,6 2%4 0% 4%4,6 0% 3%4
Late toxicity 1≥ G3 1%2 12%4,5 0% 0% -
Local control 1-y-LC: 94% Actuarial-LC: 95% NA8 NA8 1-y-LC: 100% Actuarial-LC: 100% Actuarial-LC: 89%
  1. 1Toxicity was assessed either by number or by lesion; 2Bile duct stricture; 3Radiation induced liver disease (RILD); 4Pulmonary toxicity; 5Brachial plexopathy; 6Data show overall toxicity; 7Minimum follow up 3 months; 8Local control not reported. RT: radiotherapy, fx: fractions, LC: local control, LN: lymph node, y: year, NA: not applicable.